Wall Street experts predict that ArriVent BioPharma, Inc. (AVBP) may climb by 72.44%. Check this out before making any investment decisions.
ArriVent BioPharma, Inc. (AVBP) has seen its shares rise 6.2% recently, with Wall Street analysts projecting an average short-term price target of $42.92, suggesting a potential 72.4% upside. This optimism is supported by upward revisions in earnings estimates and a Zacks Rank #2 (Buy), indicating strong near-term potential despite general cautions about relying solely on price targets.
AVBP Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for ArriVent BioPharma Inc (AVBP), indicating a "Strong Buy" consensus based on various technical indicators and moving averages. It details specific support and resistance levels, momentum indicators like RSI and MACD, and how the stock is performing relative to its 20-day, 60-day, and 200-day moving averages. As of April 2, 2026, AVBP's share price is $24.89, trading above its key moving averages, suggesting a bullish outlook.
Avoiding Lag: Real-Time Signals in (AVBP) Movement
This article provides real-time signals for Arrivent Biopharma Inc. (NASDAQ: AVBP) based on AI models. It highlights a positive near-term sentiment while noting a mid-term weak bias within a long-term strong context. The analysis includes various trading strategies, support/resistance levels across different timeframes, and emphasizes an exceptional risk-reward short setup.
Clear Street Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation
Clear Street has initiated coverage of ArriVent BioPharma (AVBP) with a Buy recommendation. This suggests a positive outlook from the financial services firm regarding the company's stock performance. Investors tracking AVBP may consider this new analyst coverage as a potential factor in their investment decisions.
Clear Street Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation
Clear Street has initiated coverage of ArriVent BioPharma (AVBP) with a Buy recommendation. This move suggests a positive outlook on the biopharmaceutical company's prospects. Investors may view this as a signal for potential growth in AVBP's stock.
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Recommendation of "Moderate Buy" by Brokerages
ArriVent BioPharma (NASDAQ:AVBP) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month target price of $41.67. Institutional ownership stands at approximately 9.48%, with increased positions from firms like Infinitum Asset Management and Suvretta Capital. The company recently reported better-than-expected Q1 EPS and is actively developing targeted cancer therapies.
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum Shift
ArriVent BioPharma (AVBP) has attracted investor attention due to recent trading activity. Despite being a loss-making company with a stated value score of 3 and trading at a large intrinsic discount (88.2% to its estimated fair value of US$181.15), its P/B ratio of 3.1x is higher than the US Biotechs industry average, yet significantly lower than its direct peer set. This suggests a mixed valuation signal, prompting investors to scrutinize underlying data.
ArriVent to present preclinical cancer drug data at AACR 2026
ArriVent BioPharma will present new preclinical data on its proprietary cancer drug, AVB-710, at the American Association for Cancer Research (AACR) annual meeting in 2026. The presentation will detail the in-vitro and in-vivo activities of AVB-710, an investigational antibody-drug conjugate (ADC), offering insights into its potential therapeutic applications. Further details on the presentation will be announced at a later date.
B. Riley Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45
B. Riley Securities has reiterated its Buy rating on ArriVent BioPharma (NASDAQ:AVBP) and increased its price target for the company's stock to $45. The article notes that this is a "headline only" analysis, primarily serving as an alert for real-time intelligence used by traders.
ArriVent BioPharma (NASDAQ:AVBP) Upgraded to Strong-Buy at Truist Financial
Truist Financial has upgraded ArriVent BioPharma (NASDAQ:AVBP) to a "strong-buy" rating, contributing to a consensus "Moderate Buy" rating and an average price target of $41.67 among analysts. The clinical-stage oncology biotech, which is developing targeted therapies for NSCLC including Furmonertinib, reported better-than-expected Q4 EPS. Several institutional investors have also recently increased their positions in the company.
ArriVent to present preclinical cancer drug data at AACR 2026
ArriVent Bio revealed it will present preclinical data on its pipeline cancer drugs at the American Association for Cancer Research (AACR) annual meeting in 2026. The presentation will include findings on AVT-001 and AVT-002, highlighting their potential in treating various cancers. This announcement signals ArriVent's progress in oncology drug development.
ArriVent to Present Preclinical Cancer Drug Data at AACR 2026
ArriVent BioPharma Inc. (Nasdaq: AVBP) will present preclinical data for two cancer drug candidates, firmonertinib and ARR-002, at the American Association for Cancer Research Annual Meeting 2026. Firmonertinib, an EGFR inhibitor, showed efficacy against classical and exon 20 insertion EGFR mutations in non-small cell lung cancer, while ARR-002, a dual-target antibody drug conjugate, demonstrated improved tumor response in ovarian and endometrial cancer models compared to single-target therapies. These presentations build on earlier findings and support continued development of both programs.
Is ArriVent BioPharma (AVBP) Offering Value After Recent Share Price Pullback?
This article analyzes ArriVent BioPharma (AVBP) to determine if its current share price of around US$22.86 presents a fair valuation, especially after a recent 5.1% decline over the last week. Using a Discounted Cash Flow (DCF) analysis, the stock appears significantly undervalued by 85.1%, with an estimated intrinsic value of $153.23 per share. However, its Price to Book (P/B) ratio of 3.29x is above the biotech industry average, suggesting it's about right by that metric.
ArriVent BioPharma (AVBP) to showcase firmonertinib and ARR-002 preclinical data at AACR 2026
ArriVent BioPharma (AVBP) announced it will present preclinical data for its EGFR inhibitor firmonertinib and its novel dual-target MUC16/NaPi2b antibody drug conjugate (ADC) ARR-002 at the 2026 AACR Annual Meeting. The firmonertinib presentation will include high-resolution crystal structure data supporting its ongoing Phase 3 study in non-small cell lung cancer, while ARR-002 data will highlight its potential for ovarian and endometrial cancers. These presentations underscore ArriVent's commitment to advancing innovative biopharmaceutical therapeutics in oncology.
ArriVent to present preclinical data on firmonertinib and dual-target ADC ARR-002 at AACR 2026
ArriVent BioPharma (AVBP) announced it will present preclinical data on its drug candidates, firmonertinib and ARR-002, at AACR 2026. Firmonertinib data will cover its high-resolution structure, broad EGFR activity including ex20ins, potent in vitro/in vivo efficacy, and brain penetrance, supporting ongoing global Phase 3 trials. ARR-002, a MUC16/NaPi2b tetravalent ADC, will have its superior in vivo efficacy, dual-target engagement, enhanced internalization, and favorable tolerability described.
ArriVent BioPharma, Inc. $AVBP Shares Sold by Hidden Lake Asset Management LP
Hidden Lake Asset Management LP significantly reduced its stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) by 48.3% during the third quarter, selling 292,815 shares and now owning 314,036 shares valued at $5,794,000. Despite this sale, other institutional investors like Vanguard Group Inc. and UBS Group AG increased their holdings. The company currently holds a consensus "Moderate Buy" rating from analysts with an average price target of $40.78, and recently reported better-than-expected quarterly earnings.
Anson Funds Management LP Makes New Investment in ArriVent BioPharma, Inc. $AVBP
Anson Funds Management LP has acquired a new stake in ArriVent BioPharma (NASDAQ:AVBP), purchasing 99,887 shares valued at approximately $1.84 million, representing about 0.24% ownership. Other institutional investors have also adjusted their positions, bringing total institutional ownership to around 9.48%. Despite a negative trailing PE, analysts maintain a "Moderate Buy" consensus for AVBP, with an average price target of $40.78.
Suvretta Capital Management LLC Buys 290,664 Shares of ArriVent BioPharma, Inc. $AVBP
Suvretta Capital Management LLC increased its stake in ArriVent BioPharma, Inc. (AVBP) by 8.5%, purchasing an additional 290,664 shares to bring its total holding to 3,703,452 shares, valued at approximately $68.33 million. This makes ArriVent BioPharma the 17th largest position in Suvretta's portfolio, representing about 8.97% of the company's stock. The article also notes positive analyst sentiment with an average "Moderate Buy" rating and a target price of $40.78 for AVBP, following the company's recent beat on quarterly EPS estimates.
ArriVent BioPharma's (AVBP) Buy Rating Reaffirmed at BTIG Research
BTIG Research has reaffirmed a "Buy" rating and a $42.00 price target for ArriVent BioPharma (AVBP), indicating a potential upside of over 70%. The clinical-stage oncology biotech, which is developing Furmonertinib for NSCLC, holds a consensus "Moderate Buy" rating among analysts with an average price target of $40.78. Institutional investors like Vanguard and UBS have also increased their stakes in the company.
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Chemomab Therapeutics (CMMB) and Reviva Pharmaceuticals Holdings (RVPH)
Three healthcare companies, ArriVent BioPharma, Inc. (AVBP), Chemomab Therapeutics (CMMB), and Reviva Pharmaceuticals Holdings (RVPH), have received bullish sentiments from analysts. LifeSci Capital maintained a Buy rating on ArriVent BioPharma with a $42.00 price target, while Maxim Group analysts maintained Buy ratings for Chemomab Therapeutics and Reviva Pharmaceuticals Holdings with price targets of $5.00 and $1.00, respectively. The consensus for all three companies is either a Strong Buy or Moderate Buy, indicating positive outlooks from the analyst community.
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
BTIG analyst Jeet Mukherjee maintained a Buy rating on ArriVent BioPharma (ARVN) with a $42 price target, citing the undervaluation of its EGFR franchise. The rating is driven by the potential of firmonertinib in NSCLC, especially given strong prior data and existing approval in China, and its efficacy in PACC mutations. Additionally, the emerging ADC portfolio offers long-term optionality not yet reflected in the current stock valuation.
ArriVent Reports 2025 Results, Plans Phase 3 Data for Firmonertinib
ArriVent BioPharma Inc. reported financial results for 2025, expecting pivotal Phase 3 data in mid-2026 for firmonertinib, its lung cancer drug candidate. The company also announced the first patient dosed in the ALPACCA trial and progress in its antibody-drug conjugate pipeline. ArriVent finished 2025 with $312.8 million in cash, projected to fund operations into Q3 2027, despite an increased net loss and R&D expenses.
Is ArriVent BioPharma, Inc. (AVBP) Shares Surpassing Other Medical Stocks in Performance This Year?
ArriVent BioPharma (AVBP) has significantly outperformed its Medical sector peers this year, with a 23.3% gain compared to the sector's average return of -0.7%. The company holds a Zacks Rank of #2 (Buy), and analysts have raised full-year earnings estimates by 5%. Another strong performer in the sector is Ocugen (OCGN), also with a 23% gain and a Zacks Rank #2 (Buy).
Guggenheim Sticks to Their Buy Rating for ArriVent BioPharma, Inc. (AVBP)
Guggenheim analyst Michael Schmidt reiterated a Buy rating on ArriVent BioPharma, Inc. (AVBP) with a $45.00 price target. This comes despite the company reporting a wider GAAP net loss of $34.98 million for the quarter ending September 30, compared to $20.56 million in the previous year. Other analysts also issued Buy ratings, while one maintained a Hold.
A Look At ArriVent BioPharma (AVBP) Valuation After Recent Share Price Swings
ArriVent BioPharma (AVBP) has experienced recent share price volatility, with a 7.2% decline in one day but a 7% gain over the past month and a 12.6% year-to-date increase. As a clinical-stage company with no revenue and a net loss of US$166.308 million, its valuation is complex. While its price-to-book ratio of 3.4x is higher than the average US biotech peer, a discounted cash flow model suggests the stock is heavily undervalued at $23.43 compared to an estimated future value of $169.12.
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $33.00
Citigroup raised its price target for ArriVent BioPharma (NASDAQ:AVBP) from $31.00 to $33.00, maintaining a "buy" rating and suggesting a nearly 39% upside. This comes as the company beat its quarterly EPS consensus, trading down 5.9% to $23.76 on Friday, March 6, 2026. The biotech firm also saw unusual call buying activity, indicating speculative bullish interest, though institutional ownership remains relatively low.
Oppenheimer Remains a Buy on ArriVent BioPharma, Inc. (AVBP)
Oppenheimer analyst Jeff Jones reiterated a Buy rating on ArriVent BioPharma, Inc. (AVBP) with a price target of $50.00. Another Buy rating was issued by Guggenheim, while TipRanks – OpenAI maintained a Hold rating. The company reported a GAAP net loss of $34.98 million for the quarter ending September 30, an increase from the $20.56 million loss in the prior year.
Is ArriVent BioPharma (AVBP) Pricing Reflect Its DCF Value After Recent Share Gains
This article analyzes ArriVent BioPharma's current share price against its underlying worth using two valuation approaches. A Discounted Cash Flow (DCF) model suggests the stock is significantly undervalued by 92.3%, with an estimated intrinsic value of $327.51 per share compared to its recent price of US$25.25. The Price-to-Book (P/B) ratio of 3.42x is close to its peer group average, indicating it's "about right" based on that metric, though a proprietary Fair Ratio is unavailable.
ArriVent BioPharma Reports Full Year 2025 Financial Results
ArriVent BioPharma reported its full-year 2025 financial results, highlighting progress in its oncology pipeline, especially with firmonertinib for NSCLC and its ADC program, ARR-217. The company anticipates topline Phase 3 data for firmonertinib in mid-2026 and expects its current cash and investments of $312.8 million to fund operations into Q3 2027. ArriVent is focused on addressing unmet medical needs in cancer through differentiated medicines.
ArriVent BioPharma Sees Unusually High Options Volume (NASDAQ:AVBP)
ArriVent BioPharma (NASDAQ:AVBP) experienced unusually high options trading volume on Friday, with traders acquiring 1,832 call options, a 321% increase over the average. The company holds a "Moderate Buy" consensus rating from analysts with an average price target of $40.22, despite some mixed recent analyst notes. AVBP's stock traded down to $24.05 after reporting better-than-expected quarterly EPS, and institutional investors own approximately 9.48% of the company.
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $44.00
HC Wainwright recently raised its price target for ArriVent BioPharma (NASDAQ:AVBP) to $44.00 from $42.00, maintaining a "buy" rating, indicating a potential upside of over 74%. The consensus among analysts is a "Moderate Buy" with an average target of $40.22, reflecting positive sentiment. The company recently reported better-than-expected Q1 EPS of -$0.78 and has a market capitalization of approximately $1.04 billion.
ArriVent BioPharma Reports Full Year 2025 Financial Results
ArriVent BioPharma reported its full-year 2025 financial results, highlighting progress in its firmonertinib program for EGFR mutant NSCLC, with topline pivotal Phase 3 data expected mid-2026. The company also advanced its antibody-drug conjugate (ADC) pipeline, including ARR-217 in Phase 1 clinical development. ArriVent concluded 2025 with $312.8 million in cash and investments, projected to fund operations into Q3 2027.
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of "Moderate Buy" by Analysts
Analysts have given ArriVent BioPharma, Inc. (NASDAQ:AVBP) a "Moderate Buy" consensus rating based on recommendations from twelve research firms, with an average one-year price target of $40.00. Key institutional investors have increased their stakes, and the stock recently saw a 10.9% rise. The company specializes in clinical-stage biopharmaceutical development, focusing on targeted cancer therapies like Furmonertinib for NSCLC.
ArriVent lines up mid-2026 lung cancer data, backed by $312.8M cash
ArriVent BioPharma reported its full-year 2025 financial results, ending the year with $312.8 million in cash and investments, projected to fund operations into Q3 2027. The company announced significant clinical progress, including completed enrollment in the pivotal Phase 3 FURVENT study for EGFR exon 20 insertion NSCLC and FDA Breakthrough Therapy designation for firmonertinib. Topline data for this study are expected in mid-2026, alongside advancements in their antibody-drug conjugate (ADC) pipeline, with ARR-217 entering Phase 1.
ArriVent BioPharma Inc reports results for the quarter ended December 31 - Earnings Summary
ArriVent BioPharma Inc has released its earnings summary for the quarter that ended on December 31. The report was provided by Refinitiv and is relevant to analysts and investors tracking the company's financial performance.
AVBP PE Ratio & Valuation, Is AVBP Overvalued
This article provides a valuation analysis of ArriVent BioPharma Inc (AVBP), indicating it is currently in the "Fair zone" based on its forward PS ratio. It details various financial metrics such as Price-to-Book ratio, Free Cash Flow yield, and compares its valuation multipliers to industry averages. The analysis suggests that while AVBP's robust revenue growth is noted, its P/S ratio being significantly above the industry average might be unsustainable.
(AVBP) Movement Within Algorithmic Entry Frameworks
This article provides an algorithmic analysis of Arrivent Biopharma Inc. (NASDAQ: AVBP), highlighting conflicting sentiment across different time horizons, suggesting choppy conditions for the stock. It details a strong risk-reward setup with an exceptional 53.7:1 ratio targeting a 14.9% gain versus 0.3% risk. The analysis includes AI-generated institutional trading strategies for various risk profiles, encompassing position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
AVBP Stock News Today | Earnings, Events & Price Alerts
This page provides recent news and events related to AVBP stock, including articles on growth prospects for the EGFR-NSCLC market and regulatory updates for oncology drugs. A significant event highlighted is ArriVent BioPharma dosing the first patient in its global Phase 3 ALPACCA study for firmonertinib, aimed at treating EGFR PACC mutant non-small cell lung cancer. The article also mentions past financial updates and analyst recommendations for other companies.
AVBP - Arrivent Biopharma Inc Latest Stock News & Market Updates
This page provides the latest news and market updates for Arrivent Biopharma Inc. (AVBP), a clinical-stage biopharmaceutical company focused on oncology. Key news includes financial results, clinical trial progress for its lead candidate firmonertinib in NSCLC, and advancements in its antibody-drug conjugate (ADC) pipeline. The company also reports on corporate developments such as board appointments and financing events, serving as a comprehensive resource for investors and traders.
Hillhouse discloses 9.5% ArriVent BioPharma (AVBP) ownership stake
Hillhouse Investment Management, Ltd. has disclosed a 9.5% ownership stake in ArriVent BioPharma (AVBP), holding 3,929,117 shares of common stock. This information was reported in an amended Schedule 13G filing, reflecting their beneficial ownership as of November 7, 2025. Hillhouse maintains sole voting and dispositive power over these shares, which are held through affiliated entities.
ArriVent BioPharma (AVBP) Projected to Post Earnings on Monday
ArriVent BioPharma (AVBP) is scheduled to release its Q4 2025 earnings before market open on Monday, March 2nd, with analysts expecting a loss of ($0.87) per share. The company currently holds a "Moderate Buy" consensus rating and a target price of $40 among analysts, suggesting significant upside. Institutional investors, including Infinitum Asset Management and Suvretta Capital, have notably increased their positions in AVBP during the fourth quarter.
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of "Moderate Buy" from Analysts
ArriVent BioPharma, Inc. (NASDAQ:AVBP) has received a consensus "Moderate Buy" rating from twelve analysts, with an average 12-month price target of $40.00. The company, a clinical-stage oncology biotech, is developing furmonertinib for non-small cell lung cancer, and currently trades around $21.86. Institutional investors hold approximately 9.48% of the stock.
Trading Systems Reacting to (AVBP) Volatility
Trading systems are reacting to volatility in Arrivent Biopharma Inc. (NASDAQ: AVBP), with weak near-term sentiment potentially leading to bearish positioning. AI models have generated three trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The stock shows a mid-channel oscillation pattern, presenting a high risk-reward setup.
$207B Market Shift: The Race for Fast Track Approval in Oncology
The FDA is accelerating drug approvals in oncology, particularly for targeted therapies addressing high-unmet-need solid tumors, creating a significant market opportunity expected to reach $326.82 billion by 2031. Companies like Oncolytics Biotech Inc., Relay Therapeutics, MAIA Biotechnology, Zai Lab, and Arrivent BioPharma are leveraging expedited pathways such as Fast Track and Breakthrough Therapy designations to speed up development and capitalize on this regulatory momentum. These designations, granted for treatments showing meaningful advantages or significant improvement over existing options, are proving to be primary value drivers for growth in the biotech sector.
How Arrivent Biopharma Inc. (AVBP) Affects Rotational Strategy Timing
This article analyzes Arrivent Biopharma Inc. (AVBP) through the lens of rotational strategy timing, highlighting strong near- and mid-term sentiment which could extend to the long term. It identifies a mid-channel oscillation pattern and an exceptional risk-reward short setup with 15.9% downside target versus 0.3% risk. The piece also provides institutional trading strategies including position, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis.
JonesTrading Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45
JonesTrading analyst Soumit Roy has re-affirmed a "Buy" rating for ArriVent BioPharma (AVBP.US) and maintained a target price of $45. According to TipRanks data, the analyst has a 27.5% success rate and an average return of -12.9% over the past year. This information is meant for informational purposes and does not constitute investment advice.
Notable Thursday Option Activity: AVBP, GRAL, APPN
This article highlights significant options trading activity for ArriVent Biopharma Inc (AVBP), Grail Inc (GRAL), and Appian Corp (APPN) on a recent Thursday. For each company, the article details the total contract volume traded, its percentage relative to the average daily trading volume, and identifies specific strike prices and expiry dates with notably high trading volume. The report indicates strong interest in particular put and call options for these stocks.
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald
Cantor Fitzgerald has reiterated its Overweight rating on ArriVent BioPharma (NASDAQ:AVBP), maintaining a positive outlook due to the company's upcoming Phase 3 readout for firmonertinib in early 2026. The drug is being developed for the first-line treatment of non-small cell lung cancer with exon 20 insertion mutations. Despite current stock valuation appearing slightly overvalued, analyst interest in ArriVent's potential in oncology is growing, with multiple firms initiating or reiterating Buy/Outperform ratings.
(AVBP) and the Role of Price-Sensitive Allocations
This article analyzes Arrivent Biopharma Inc. (NASDAQ: AVBP) with a focus on its near-term strong sentiment potentially challenging persistent mid and long-term weakness. It highlights an exceptional risk-reward setup targeting a 20.4% gain with minimal risk and provides three distinct AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) tailored to different risk profiles. The analysis also includes a multi-timeframe signal analysis with support and resistance levels.
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald
Cantor Fitzgerald has reiterated its Overweight rating on ArriVent BioPharma (NASDAQ:AVBP), maintaining a positive outlook on the clinical-stage biopharmaceutical company. The firm's analysis focuses on ArriVent’s upcoming Phase 3 readout for firmonertinib, a tyrosine kinase inhibitor (TKI) for non-small cell lung cancer, expected in early 2026. This decision comes despite the stock appearing slightly overvalued according to InvestingPro Fair Value estimates and industry discussions about a competitor's potentially earlier results.
